Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis

Li Shiun Chen; Timothy Baker; Rayjean J. Hung; Amy Horton; Robert Culverhouse; Sarah Hartz; Nancy Saccone; Iona Cheng; Bo Deng; Younghun Han; Helen M. Hansen; Janet Horsman; Claire Kim; Albert Rosenberger; Katja K. Aben; Angeline S. Andrew; Shen Chih Chang; Kai Uwe Saum; Hendrik Dienemann; Dorothy K. Hatsukami; Eric O. Johnson; Mala Pande; Margaret R. Wrensch; John McLaughlin; Vidar Skaug; Erik H. van der Heijden; Jason Wampfler; Angela Wenzlaff; Penella Woll; Shanbeh Zienolddiny; Heike Bickeböller; Hermann Brenner; Eric J. Duell; Aage Haugen; Irene Brüske; Lambertus A. Kiemeney; Philip Lazarus; Loic Le Marchand; Geoffrey Liu; Jose Mayordomo; Angela Risch; Ann G. Schwartz; M. Dawn Teare; Xifeng Wu; John K. Wiencke; Ping Yang; Zuo Feng Zhang; Margaret R. Spitz; Christopher I. Amos; Laura J. Bierut

doi:10.1016/j.ebiom.2016.08.012

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis

Li Shiun Chen, Timothy Baker, Rayjean J. Hung, Amy Horton, Robert Culverhouse, Sarah Hartz, Nancy Saccone, Iona Cheng, Bo Deng, Younghun Han, Helen M. Hansen, Janet Horsman, Claire Kim, Albert Rosenberger, Katja K. Aben, Angeline S. Andrew, Shen Chih Chang, Kai Uwe Saum, Hendrik Dienemann, Dorothy K. HatsukamiEric O. Johnson, Mala Pande, Margaret R. Wrensch, John McLaughlin, Vidar Skaug, Erik H. van der Heijden, Jason Wampfler, Angela Wenzlaff, Penella Woll, Shanbeh Zienolddiny, Heike Bickeböller, Hermann Brenner, Eric J. Duell, Aage Haugen, Irene Brüske, Lambertus A. Kiemeney, Philip Lazarus, Loic Le Marchand, Geoffrey Liu, Jose Mayordomo, Angela Risch, Ann G. Schwartz, M. Dawn Teare, Xifeng Wu, John K. Wiencke, Ping Yang, Zuo Feng Zhang, Margaret R. Spitz, Christopher I. Amos, Laura J. Bierut

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Background Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. Methods Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies of individuals with European ancestry who possessed varying rs16969968 genotypes (N = 12,690 ever smokers, including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium. Results Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10^–10). The CHRNA5 rs16969968 risk genotype (AA) was associated with increased risk and earlier diagnosis for lung cancer, but the beneficial effects of smoking cessation were very similar in those with and without the risk genotype. Conclusion We demonstrate that quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions for those who smoke.

Original language	English (US)
Pages (from-to)	219-226
Number of pages	8
Journal	EBioMedicine
Volume	11
DOIs	https://doi.org/10.1016/j.ebiom.2016.08.012
State	Published - Sep 1 2016

Keywords

Genetics
Lung cancer
Meta-analysis
Smoking cessation

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.ebiom.2016.08.012

Cite this

Chen, L. S., Baker, T., Hung, R. J., Horton, A., Culverhouse, R., Hartz, S., Saccone, N., Cheng, I., Deng, B., Han, Y., Hansen, H. M., Horsman, J., Kim, C., Rosenberger, A., Aben, K. K., Andrew, A. S., Chang, S. C., Saum, K. U., Dienemann, H., ... Bierut, L. J. (2016). Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis. EBioMedicine, 11, 219-226. https://doi.org/10.1016/j.ebiom.2016.08.012

Chen, LS, Baker, T, Hung, RJ, Horton, A, Culverhouse, R, Hartz, S, Saccone, N, Cheng, I, Deng, B, Han, Y, Hansen, HM, Horsman, J, Kim, C, Rosenberger, A, Aben, KK, Andrew, AS, Chang, SC, Saum, KU, Dienemann, H, Hatsukami, DK, Johnson, EO, Pande, M, Wrensch, MR, McLaughlin, J, Skaug, V, van der Heijden, EH, Wampfler, J, Wenzlaff, A, Woll, P, Zienolddiny, S, Bickeböller, H, Brenner, H, Duell, EJ, Haugen, A, Brüske, I, Kiemeney, LA, Lazarus, P, Le Marchand, L, Liu, G, Mayordomo, J, Risch, A, Schwartz, AG, Teare, MD, Wu, X, Wiencke, JK, Yang, P, Zhang, ZF, Spitz, MR, Amos, CI & Bierut, LJ 2016, 'Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis', EBioMedicine, vol. 11, pp. 219-226. https://doi.org/10.1016/j.ebiom.2016.08.012

@article{2825b544f8484afaafe7179657e8a5f8,

title = "Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis",

abstract = "Background Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. Methods Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies of individuals with European ancestry who possessed varying rs16969968 genotypes (N = 12,690 ever smokers, including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium. Results Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10–10). The CHRNA5 rs16969968 risk genotype (AA) was associated with increased risk and earlier diagnosis for lung cancer, but the beneficial effects of smoking cessation were very similar in those with and without the risk genotype. Conclusion We demonstrate that quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions for those who smoke.",

keywords = "Genetics, Lung cancer, Meta-analysis, Smoking cessation",

author = "Chen, {Li Shiun} and Timothy Baker and Hung, {Rayjean J.} and Amy Horton and Robert Culverhouse and Sarah Hartz and Nancy Saccone and Iona Cheng and Bo Deng and Younghun Han and Hansen, {Helen M.} and Janet Horsman and Claire Kim and Albert Rosenberger and Aben, {Katja K.} and Andrew, {Angeline S.} and Chang, {Shen Chih} and Saum, {Kai Uwe} and Hendrik Dienemann and Hatsukami, {Dorothy K.} and Johnson, {Eric O.} and Mala Pande and Wrensch, {Margaret R.} and John McLaughlin and Vidar Skaug and {van der Heijden}, {Erik H.} and Jason Wampfler and Angela Wenzlaff and Penella Woll and Shanbeh Zienolddiny and Heike Bickeb{\"o}ller and Hermann Brenner and Duell, {Eric J.} and Aage Haugen and Irene Br{\"u}ske and Kiemeney, {Lambertus A.} and Philip Lazarus and {Le Marchand}, Loic and Geoffrey Liu and Jose Mayordomo and Angela Risch and Schwartz, {Ann G.} and Teare, {M. Dawn} and Xifeng Wu and Wiencke, {John K.} and Ping Yang and Zhang, {Zuo Feng} and Spitz, {Margaret R.} and Amos, {Christopher I.} and Bierut, {Laura J.}",

note = "Publisher Copyright: {\textcopyright} 2016 Forschungsgesellschaft f{\"u}r Arbeitsphysiologie und Arbeitschutz e.V.",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/j.ebiom.2016.08.012",

language = "English (US)",

volume = "11",

pages = "219--226",

journal = "EBioMedicine",

issn = "2352-3964",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Genetic Risk Can Be Decreased

T2 - Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis

AU - Chen, Li Shiun

AU - Baker, Timothy

AU - Hung, Rayjean J.

AU - Horton, Amy

AU - Culverhouse, Robert

AU - Hartz, Sarah

AU - Saccone, Nancy

AU - Cheng, Iona

AU - Deng, Bo

AU - Han, Younghun

AU - Hansen, Helen M.

AU - Horsman, Janet

AU - Kim, Claire

AU - Rosenberger, Albert

AU - Aben, Katja K.

AU - Andrew, Angeline S.

AU - Chang, Shen Chih

AU - Saum, Kai Uwe

AU - Dienemann, Hendrik

AU - Hatsukami, Dorothy K.

AU - Johnson, Eric O.

AU - Pande, Mala

AU - Wrensch, Margaret R.

AU - McLaughlin, John

AU - Skaug, Vidar

AU - van der Heijden, Erik H.

AU - Wampfler, Jason

AU - Wenzlaff, Angela

AU - Woll, Penella

AU - Zienolddiny, Shanbeh

AU - Bickeböller, Heike

AU - Brenner, Hermann

AU - Duell, Eric J.

AU - Haugen, Aage

AU - Brüske, Irene

AU - Kiemeney, Lambertus A.

AU - Lazarus, Philip

AU - Le Marchand, Loic

AU - Liu, Geoffrey

AU - Mayordomo, Jose

AU - Risch, Angela

AU - Schwartz, Ann G.

AU - Teare, M. Dawn

AU - Wu, Xifeng

AU - Wiencke, John K.

AU - Yang, Ping

AU - Zhang, Zuo Feng

AU - Spitz, Margaret R.

AU - Amos, Christopher I.

AU - Bierut, Laura J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. Methods Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies of individuals with European ancestry who possessed varying rs16969968 genotypes (N = 12,690 ever smokers, including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium. Results Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10–10). The CHRNA5 rs16969968 risk genotype (AA) was associated with increased risk and earlier diagnosis for lung cancer, but the beneficial effects of smoking cessation were very similar in those with and without the risk genotype. Conclusion We demonstrate that quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions for those who smoke.

AB - Background Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. Methods Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies of individuals with European ancestry who possessed varying rs16969968 genotypes (N = 12,690 ever smokers, including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium. Results Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10–10). The CHRNA5 rs16969968 risk genotype (AA) was associated with increased risk and earlier diagnosis for lung cancer, but the beneficial effects of smoking cessation were very similar in those with and without the risk genotype. Conclusion We demonstrate that quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions for those who smoke.

KW - Genetics

KW - Lung cancer

KW - Meta-analysis

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=84994860533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994860533&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2016.08.012

DO - 10.1016/j.ebiom.2016.08.012

M3 - Article

C2 - 27543155

AN - SCOPUS:84994860533

SN - 2352-3964

VL - 11

SP - 219

EP - 226

JO - EBioMedicine

JF - EBioMedicine

ER -

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this